Anthropic Buys One-Person Biotech Mithril

Anthropic said on Oct. 27 that it has acquired Mithril Medicine, a one-person company developing treatments for two rare forms of muscular dystrophy, and published early results from drug development work with six outside partners, including Bristol Myers Squibb. The company did not disclose the price of the deal.

Key takeaways

• Anthropic acquired Mithril Medicine, whose founder used Claude to run experiments with 11 external labs and took one candidate from idea to promising mouse results in under 18 months.
• Six partners — Generate Biomedicines, Divergence Labs, BigHat Biosciences, Enveda, The Column Group and Bristol Myers Squibb — reported results ranging from antibody design to regulatory paperwork.
• Most of the work is preclinical. Anthropic says a Mithril drug could enter human trials as early as late 2028 if the candidates hold up.

What is Mithril Medicine?

Mithril was run by a single founder, Cody Tranbarger, according to Anthropic's research post. He used Claude to organize contracts, logistics and experiments across 11 outside labs and handed off many other operational tasks to the model.

Tranbarger now works at Anthropic and plans several new programs. Endpoints News reported that the startup was backed by Atlas Venture.

Claude drug discovery results from six partners

Anthropic said its scientists spent several months in research partnerships with six organizations, each covering a different stage of drug development.

At Generate Biomedicines, six scientists used Claude Code to redesign part of the genetic instructions for a CAR T-cell therapy aimed at solid tumors. One design was about 70% shorter than the standard version. In lab tests, it allowed roughly 10 times as many receptors, killed tumor cells more efficiently and stayed active longer.

Divergence Labs, which is working on food allergy drugs, had Claude generate about 35,000 antibody designs in roughly a month, largely autonomously. Early tests found 20 designs that could dislodge the allergy antibody IgE from immune cells, and three of them did so more than the standard medication.

BigHat Biosciences connected Claude to its lab data system. The lab made and tested about 1,010 variants of two antibody fragments in about 10 weeks. The best versions bound more than 10 times more tightly; one stayed in solution at a temperature 18°C higher, and another clumped more than 100 times more slowly.

AI for regulatory filings and clinical trials

Enveda, whose manufacturing chemists had spent up to 75% of their time on paperwork, ran Claude over 1,061 pages of documents. Claude caught all 11 issues human reviewers found and flagged seven they missed, cutting human review time 89%, from more than 25 hours to under three. One regulatory document Claude drafted took four hours, against about three months by hand.

The Column Group is setting up Pleiades, a company that will use Claude to run drug programs. Its first Claude skill, which judges whether drug targets are worth pursuing, was evaluated on 45 target-disease pairs.

Bristol Myers Squibb is using Claude to assess trial plans for an early-stage drug and estimate their odds of success. "From a single prompt, Claude generated a robust initial analysis that helped inform our assessment," said Michael Pourdehnad, MD, head of early clinical development for hematology, oncology and cell therapy at BMS. The companies plan to expand the work in 2027.

Context: the AI drug race

The deal extends a run of life sciences moves by Anthropic, which bought computational biology startup Coefficient Bio in April and launched its Claude Science research workbench on June 30. Rival OpenAI announced on Oct. 20 that it would acquire Orchestra Bio, a drug development operations platform.

What's next

Anthropic described the work as early and mostly preclinical, and said it plans to scale it up substantially. None of the partner results have been tested in people, and the company has not published peer-reviewed data on them.

FAQ

How much did Anthropic pay for Mithril Medicine? Anthropic did not disclose the price or other deal terms.

Is any Claude-designed drug in human trials? No. Anthropic said the Mithril candidate could enter human clinical trials as early as late 2028, if the results continue to hold up.

Which Claude model was used? Anthropic's post refers only to "Claude" and Claude Code and does not name a model version.

References

• Early progress on accelerating drug development with Claude — Anthropic (Oct. 27, 2026)
• Anthropic's latest biotech buy is a one-man stealth startup run by a pseudonymous Twitter poster — Endpoints News (Oct. 27, 2026)
• Anthropic buys drug startup, reports Claude results with 6 partners — Becker's Hospital Review (Oct. 27, 2026)